Adieu to Aduhelm: Biogen Stops Marketing Antibody
The company announced it would halt its post-market trial and stop selling the drug; the rights to it now revert to Swiss company Neurimmune.
47 RESULTS
Sort By:
The company announced it would halt its post-market trial and stop selling the drug; the rights to it now revert to Swiss company Neurimmune.
Based on exploratory endpoints and post hoc analyses, TauRx claims HMTM benefits a subgroup of participants with MCI. Trialists are unconvinced.